JP2021535161A5 - - Google Patents
Info
- Publication number
- JP2021535161A5 JP2021535161A5 JP2021510984A JP2021510984A JP2021535161A5 JP 2021535161 A5 JP2021535161 A5 JP 2021535161A5 JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021535161 A5 JP2021535161 A5 JP 2021535161A5
- Authority
- JP
- Japan
- Prior art keywords
- hae
- antibody
- treatment period
- weeks
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094996A JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725216P | 2018-08-30 | 2018-08-30 | |
| US62/725,216 | 2018-08-30 | ||
| US201962808612P | 2019-02-21 | 2019-02-21 | |
| US62/808,612 | 2019-02-21 | ||
| PCT/US2019/048961 WO2020047352A1 (en) | 2018-08-30 | 2019-08-30 | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094996A Division JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535161A JP2021535161A (ja) | 2021-12-16 |
| JP2021535161A5 true JP2021535161A5 (https=) | 2022-09-05 |
| JP7585193B2 JP7585193B2 (ja) | 2024-11-18 |
Family
ID=67953889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510984A Active JP7585193B2 (ja) | 2018-08-30 | 2019-08-30 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
| JP2024094996A Pending JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094996A Pending JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200109214A1 (https=) |
| EP (1) | EP3843840A1 (https=) |
| JP (2) | JP7585193B2 (https=) |
| KR (1) | KR20210053928A (https=) |
| CN (1) | CN113056304A (https=) |
| AU (2) | AU2019328324B2 (https=) |
| BR (1) | BR112021003789A2 (https=) |
| CA (1) | CA3110689A1 (https=) |
| IL (1) | IL281063A (https=) |
| MA (1) | MA53490A (https=) |
| MX (1) | MX2021002349A (https=) |
| WO (1) | WO2020047352A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| AU2014240045A1 (en) | 2013-03-15 | 2015-09-10 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CN113056304A (zh) * | 2018-08-30 | 2021-06-29 | 戴埃克斯有限公司 | 用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途 |
| EP4090427A1 (en) * | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| WO1995021601A2 (en) | 1994-01-11 | 1995-08-17 | Protein Engineering Corporation | Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| ES2348230T3 (es) | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| KR102320178B1 (ko) * | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| AU2014240045A1 (en) * | 2013-03-15 | 2015-09-10 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| US10428158B2 (en) * | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| KR102607829B1 (ko) * | 2015-03-30 | 2023-12-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 |
| EP3387018A1 (en) * | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| TW201727079A (zh) * | 2015-12-18 | 2017-08-01 | 葛萊兒明尼蘇達股份有限公司 | 波紋管安裝及保留方法 |
| CN113056304A (zh) * | 2018-08-30 | 2021-06-29 | 戴埃克斯有限公司 | 用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途 |
-
2019
- 2019-08-30 CN CN201980072190.9A patent/CN113056304A/zh active Pending
- 2019-08-30 JP JP2021510984A patent/JP7585193B2/ja active Active
- 2019-08-30 KR KR1020217009365A patent/KR20210053928A/ko not_active Ceased
- 2019-08-30 AU AU2019328324A patent/AU2019328324B2/en active Active
- 2019-08-30 BR BR112021003789-6A patent/BR112021003789A2/pt unknown
- 2019-08-30 EP EP19768977.1A patent/EP3843840A1/en active Pending
- 2019-08-30 CA CA3110689A patent/CA3110689A1/en active Pending
- 2019-08-30 US US16/556,524 patent/US20200109214A1/en not_active Abandoned
- 2019-08-30 MX MX2021002349A patent/MX2021002349A/es unknown
- 2019-08-30 WO PCT/US2019/048961 patent/WO2020047352A1/en not_active Ceased
- 2019-08-30 MA MA053490A patent/MA53490A/fr unknown
-
2021
- 2021-02-23 IL IL281063A patent/IL281063A/en unknown
-
2022
- 2022-05-16 US US17/745,770 patent/US20230104754A1/en active Pending
-
2024
- 2024-06-12 JP JP2024094996A patent/JP2024113183A/ja active Pending
-
2025
- 2025-09-15 AU AU2025230807A patent/AU2025230807A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535161A5 (https=) | ||
| JP2022033868A5 (https=) | ||
| US20240052058A1 (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| JP2019501886A5 (https=) | ||
| JP2024113183A5 (https=) | ||
| JP2020002171A5 (https=) | ||
| TWI837532B (zh) | 治療潰瘍性結腸炎之方法 | |
| JP2022525164A5 (https=) | ||
| JP2018514510A5 (https=) | ||
| Reisch et al. | Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function | |
| JP2019514974A5 (https=) | ||
| JP2023527542A5 (https=) | ||
| WO2023144699A1 (en) | Methods for treatment of subjects with plaque psoriasis of the scalp | |
| Takeuchi et al. | OP0040 adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (Surprise Study) | |
| JP2023510854A5 (https=) | ||
| JP2021523138A5 (https=) | ||
| UA127588C2 (uk) | Способи застосування та композиції, які містять дулаглутид | |
| JP2022513029A5 (https=) | ||
| KR20170118830A (ko) | 조현병의 치료를 위한 일로페리돈 | |
| US20250345418A1 (en) | Methods of treating al amyloidosis | |
| JP2024503379A5 (https=) | ||
| JP2024522620A5 (https=) | ||
| NZ783274B2 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| NZ783274A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| Dall'Era et al. | FC 035 VOCLOSPORIN INCREASES RENAL RESPONSE AT COMMONLY USED UPCR THRESHOLDS IN PATIENTS WITH LUPUS NEPHRITIS |